Joseph Schwartz
Stock Analyst at Leerink Partners
(4.15)
# 446
Out of 5,241 analysts
148
Total ratings
36.84%
Success rate
21.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Atrium Therapeutics | Initiates: Outperform | $25 | $13.25 | +88.68% | 5 | May 15, 2026 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | $9 | $4.71 | +91.29% | 4 | May 14, 2026 | |
| INSM Insmed | Maintains: Outperform | $210 → $215 | $109.83 | +95.76% | 5 | Mar 24, 2026 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $6 → $1 | $0.33 | +203.95% | 8 | Feb 24, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $24.96 | +180.50% | 7 | Dec 30, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $54.52 | +193.50% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $14.27 | -1.89% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $2.30 | -13.04% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $52.12 | +15.12% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $15.29 | +4.64% | 7 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $60 | $27.14 | +121.08% | 3 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $115 | $60.12 | +91.28% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $36.98 | +137.97% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $17.96 | -16.48% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $26.75 | -25.23% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $6.73 | +78.31% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $25.59 | +9.42% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $42.73 | -6.39% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $6.84 | +75.44% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.24 | +3,236.11% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $72.45 | -33.75% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $29.47 | -38.92% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $73.83 | -53.95% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $240.43 | -32.20% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.58 | +1,995.24% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.28 | +405.84% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $33.33 | -9.99% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $103.46 | -71.00% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.60 | +650.00% | 2 | Sep 26, 2017 |
Atrium Therapeutics
May 15, 2026
Initiates: Outperform
Price Target: $25
Current: $13.25
Upside: +88.68%
AN2 Therapeutics
May 14, 2026
Upgrades: Outperform
Price Target: $9
Current: $4.71
Upside: +91.29%
Insmed
Mar 24, 2026
Maintains: Outperform
Price Target: $210 → $215
Current: $109.83
Upside: +95.76%
Gossamer Bio
Feb 24, 2026
Downgrades: Market Perform
Price Target: $6 → $1
Current: $0.33
Upside: +203.95%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $24.96
Upside: +180.50%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $54.52
Upside: +193.50%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $14.27
Upside: -1.89%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $2.30
Upside: -13.04%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $52.12
Upside: +15.12%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $15.29
Upside: +4.64%
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $27.14
Upside: +121.08%
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $60.12
Upside: +91.28%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $36.98
Upside: +137.97%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $17.96
Upside: -16.48%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $26.75
Upside: -25.23%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $6.73
Upside: +78.31%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $25.59
Upside: +9.42%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $42.73
Upside: -6.39%
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.84
Upside: +75.44%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.24
Upside: +3,236.11%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $72.45
Upside: -33.75%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $29.47
Upside: -38.92%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $73.83
Upside: -53.95%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $240.43
Upside: -32.20%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.58
Upside: +1,995.24%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.28
Upside: +405.84%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $33.33
Upside: -9.99%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $103.46
Upside: -71.00%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.60
Upside: +650.00%